The spironolactone renaissance

@article{Doggrell2001TheSR,
  title={The spironolactone renaissance},
  author={Sheila Anne Doggrell and Lindsay Brown},
  journal={Expert Opinion on Investigational Drugs},
  year={2001},
  volume={10},
  pages={943 - 954}
}
Until recently, spironolactone was considered only as an antagonist at the aldosterone receptors of the epithelial cells of the kidney and was used clinically in the treatment of hyperaldosteronism and, occasionally, as a K+-sparing diuretic. The spironolactone renaissance started with the experimental finding that spironolactone reversed aldosterone-induced cardiac fibrosis by a cardiac action. Experimentally, spironolactone also has direct effects on blood vessels. Spironolactone reduces… 

Aldosterone receptor blockers spironolactone and canrenone: two multivalent drugs

Both canrenone and hydrochlorothiazide can enhance the effect of treatment with ACE inhibitors and angiotensin II receptor blockers on microalbuminuria, but ALDO receptor blockers are more active.

Rapid Effects of Aldosterone and Spironolactone in the Isolated Working Rat Heart

Examination of the hemodynamic effects of aldosterone and its receptor antagonist, spironolactone in the isolated rat heart by use of the Langendorff-Neely technique demonstrates that ald testosterone and spironOLactone have rapid, positive inotropic actions on the myocardium.

Aldosterone, mineralocorticoid receptor, and heart failure

Central mineralocorticoid receptor blockade decreases plasma TNF-alpha after coronary artery ligation in rats.

Findings suggest that activation of MR in the central nervous system plays a critical role in regulating TNF-alpha release in heart failure rats, and some of the beneficial effect of blocking MR inHeart failure could be due at least in part to a reduction in TNF -alpha production.

Spironolactone in dermatology

The use of spironolactone in different skin diseases that are common in the authors' environment, dosage according to different studies, treatment recommendations and adverse effects; all of the above mentioned in order to use this drug in a daily clinical practice are discussed.

Spironolactone in Dermatology: A Mini Review

The use of spironolactone in different skin diseases that are common in the authors' environment, dosage according to different studies, treatment recommendations and adverse effects; all of the above mentioned in order to use this drug in a daily clinical practice are discussed.

The mineralocorticoid receptor blocker spironolactone lowers plasma interferon-γ and interleukin-6 in patients with type 2 diabetes and treatment-resistant hypertension

The antihypertensive action of spironolactone in resistant hypertensive patients is associated with suppressed IFN-γ and IL-6 and not IL-17A, which exerts anti-inflammatory actions in vivo on macrophages and T-cells.

Should the aldosterone-receptor antagonist – eplerenone – be used after acute myocardial infarction with left ventricular dysfunction?

  • S. Doggrell
  • Medicine
    Expert opinion on pharmacotherapy
  • 2003
Eplerenone should probably be added to the optimal therapy for use after acute MI with LV dysfunction, provided care is taken to avoid hyperkalaemia.

Determinants of spironolactone binding specificity in the mineralocorticoid receptor.

Analysis of this model in light of the experimental data suggested that spironolactone binding specificity is not governed by amino acids in the ligand-binding pocket.

Present and future pharmacotherapy for heart failure

The pharmacotherapy currently recommended by the American College of Cardiology and the American Heart Association for heart failure is a diuretic, an angiotensin-converting enzyme inhibitor (ACEI), a β-adrenoceptor antagonist and (usually) digitalis, although digitalis does not reduce mortality.

References

SHOWING 1-10 OF 69 REFERENCES

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure.

Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension.

  • A. SatoY. SuzukiT. Saruta
  • Medicine, Biology
    Hypertension research : official journal of the Japanese Society of Hypertension
  • 1999
It is concluded that spironolactone may have beneficial effects on left ventricular hypertrophy in patients with essential hypertension who are receiving an angiotensin-converting enzyme inhibitor.

Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure.

Spironolactone improves endothelial dysfunction, increases NO bioactivity, and inhibits vascular Ang I/Ang II conversion in patients with heart failure, providing novel mechanisms for its beneficial effect on cardiovascular mortality.

Effect of spironolactone and its metabolites on contractile property of isolated rat aorta rings.

The effects of spironolactone, canrenone, and potassium canrenoate on contractile properties of isolated rat aorta rings are evaluated to suggest that these drugs could act through an inhibition of voltage-dependent Ca2+ channels.
...